Literature DB >> 23966429

Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?

Carla M Prado1, Michael B Sawyer, Sunita Ghosh, Jessica R Lieffers, Nina Esfandiari, Sami Antoun, Vickie E Baracos.   

Abstract

BACKGROUND: Skeletal muscle wasting is considered the central feature of cachexia, but the potential for skeletal muscle anabolism in patients with advanced cancer is unproven.
OBJECTIVE: We investigated the clinical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabolism.
DESIGN: We conducted a quantitative analysis of computed tomography (CT) images for the loss and gain of muscle in population-based cohorts of advanced cancer patients (lung, colorectal, and pancreas cancer and cholangiocarcinoma) in a longitudinal observational study.
RESULTS: Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4%, and muscle was stable in 45.6% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with >90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain.
CONCLUSIONS: A window of anabolic potential exists at defined early phases of the disease trajectory (>90 d survival), creating an opportunity for nutritional intervention to stop or reverse cachexia. Cancer patients within 90 d of death have a low likelihood of anabolic potential.

Entities:  

Mesh:

Year:  2013        PMID: 23966429     DOI: 10.3945/ajcn.113.060228

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  75 in total

1.  Significant publications for pharmacy nutrition support practice in 2013.

Authors:  Roland N Dickerson; Vanessa J Kumpf; Carol J Rollins; Eric H Frankel; Michael D Kraft; Todd W Canada; Catherine M Crill
Journal:  Hosp Pharm       Date:  2014-09

Review 2.  Chemotherapy-Induced Sarcopenia.

Authors:  Federico Bozzetti
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

Review 3.  The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on clinical outcome in abdominal malignancy: a systematic review.

Authors:  D J Gibson; S T Burden; B J Strauss; C Todd; S Lal
Journal:  Eur J Clin Nutr       Date:  2015-03-18       Impact factor: 4.016

4.  Clinical significance of weight changes at diagnosis in solid tumours.

Authors:  Niamh O'Donoghue; Shiva Shrotriya; Aynur Aktas; Barbara Hullihen; Serkan Ayvaz; Bassam Estfan; Declan Walsh
Journal:  Support Care Cancer       Date:  2018-11-29       Impact factor: 3.603

5.  Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Authors:  Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun
Journal:  Support Care Cancer       Date:  2017-06-08       Impact factor: 3.603

6.  Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Authors:  R S Finn; D H Ahn; M M Javle; B R Tan; C D Weekes; J C Bendell; A Patnaik; G N Khan; D Laheru; R Chavira; J Christy-Bittel; E Barrett; M B Sawyer; Tanios S Bekaii-Saab
Journal:  Invest New Drugs       Date:  2018-05-22       Impact factor: 3.850

7.  High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer.

Authors:  M P K J Engelen; A M Safar; T Bartter; F Koeman; N E P Deutz
Journal:  Ann Oncol       Date:  2015-06-25       Impact factor: 32.976

8.  Does disease duration influence the exercise training responses of patients with type 2 diabetes?

Authors:  Bong-Sup Park; Andy V Khamoui; Lee E Brown; Do-Youn Kim; Kyung-Ah Han; Kyung-Wan Min; Geun-Hee An
Journal:  J Res Med Sci       Date:  2015-01       Impact factor: 1.852

Review 9.  Resistance Exercise's Ability to Reverse Cancer-Induced Anabolic Resistance.

Authors:  Ryan N Montalvo; Justin P Hardee; Brandon N VanderVeen; James A Carson
Journal:  Exerc Sport Sci Rev       Date:  2018-10       Impact factor: 6.230

Review 10.  Protein anabolic resistance in cancer: does it really exist?

Authors:  Mariëlle P K J Engelen; Barbara S van der Meij; Nicolaas E P Deutz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2016-01       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.